Advanced Filters
noise

Lappersdorf, Germany Clinical Trials

A listing of Lappersdorf, Germany clinical trials actively recruiting patients volunteers.

Found 77 clinical trials

A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion. The prognosis of these molecularly defined tumors is to be determined in new series since survival data from older histology-based …

18 years of age All Phase 3
N Najib Ben-Khaled, MD

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev in the treatment of unresectable HCC patients.

18 years of age All Phase 2
M Martin Schecklmann

Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment

This is a randomized, controlled trial in which 72 patients with depressive disorder were treated in two study arms using the non-invasive brain stimulation method of intermittent thetaburst intermittent theta burst stimulation (iTBS). This is a wait-list control study, and the arms differ in the start of the four-week treatment …

18 - 70 years of age All Phase N/A
R Rosa Klotz, MD

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

This is an interventional, open-label, non-randomised, multicentre, single-arm phase II clinical trial. Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination chemotherapy (liposomal irinotecan, oxaliplatin, 5-fluouracil, folinic acid (NAPOX)) in cycles of 14 days. Patients with tumour response or stable disease and a resectable primary tumour …

18 years of age All Phase 2
S Selim Corbacioglu, MD

A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major …

2 - 35 years of age All Phase 2
S Sterzing, Prof. Dr.

Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases

Phase III trial comparing local control and side effects after fractionated stereotactic radiotherapy and single session radiosurgery in patients with larger brain metastases (2-4 cm)

18 years of age All Phase 3

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC. Favorable tumor responses following intralesional treatment with L19IL2/L19TNF have been observed in patients with injectable melanoma lesions of stage III or IV, for injected and non-injected …

18 - 100 years of age All Phase 2

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine …

18 - 75 years of age All Phase 1/2

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Primary objective: To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 Secondary objectives: To characterize the safety and tolerability of IMA401 To evaluate initial anti-tumor activity of IMA401 To describe the pharmacokinetics of IMA401

18 years of age All Phase 1
U Ursula Nestle, MD

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

The MIR study proved the effect of Rituximab in combination with a localized irradiation given in a standard dose. Together with the TROG 99.03 trial, this led to the recommendation of using this combined approach in early stage nodal follicular lymphoma. The GAZAI study is currently looking for the effect …

18 years of age All Phase 3

Simplify language using AI